Bicycle Therapeutics PLC Sponsored ADR $BCYC Holdings Decreased by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. lowered its stake in Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) by 70.2% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 41,368 shares of the company’s stock after selling 97,293 shares during the quarter. Harbor Capital Advisors Inc.’s holdings in Bicycle Therapeutics were worth $320,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Ausdal Financial Partners Inc. bought a new stake in shares of Bicycle Therapeutics during the 2nd quarter worth about $70,000. Sei Investments Co. bought a new position in shares of Bicycle Therapeutics in the second quarter valued at approximately $74,000. Virtus Investment Advisers LLC increased its stake in shares of Bicycle Therapeutics by 32.6% during the second quarter. Virtus Investment Advisers LLC now owns 10,821 shares of the company’s stock valued at $75,000 after acquiring an additional 2,659 shares during the period. Ameriprise Financial Inc. bought a new stake in Bicycle Therapeutics during the second quarter worth approximately $86,000. Finally, State of Tennessee Department of Treasury bought a new stake in Bicycle Therapeutics during the second quarter worth approximately $100,000. Institutional investors and hedge funds own 86.15% of the company’s stock.

Insider Transactions at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,231 shares of the company’s stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $8.41, for a total transaction of $27,172.71. Following the completion of the sale, the chief executive officer directly owned 475,310 shares of the company’s stock, valued at approximately $3,997,357.10. This represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders sold 8,527 shares of company stock worth $71,738. 8.50% of the stock is currently owned by insiders.

Bicycle Therapeutics Stock Down 0.6%

BCYC opened at $6.78 on Tuesday. The firm has a market cap of $470.33 million, a PE ratio of -1.87 and a beta of 1.47. The business has a fifty day simple moving average of $7.12 and a 200-day simple moving average of $7.46. Bicycle Therapeutics PLC Sponsored ADR has a fifty-two week low of $6.03 and a fifty-two week high of $15.47.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its earnings results on Thursday, October 30th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.24. Bicycle Therapeutics had a negative return on equity of 36.05% and a negative net margin of 884.51%.The company had revenue of $11.73 million for the quarter, compared to analyst estimates of $8.25 million. On average, equities research analysts anticipate that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on BCYC. Truist Financial assumed coverage on Bicycle Therapeutics in a research note on Monday, November 24th. They set a “hold” rating and a $10.00 price target for the company. Citizens Jmp upped their price objective on Bicycle Therapeutics from $10.00 to $12.00 and gave the company a “market outperform” rating in a report on Friday, October 31st. Citigroup reaffirmed an “outperform” rating on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $11.00 price target (down from $27.00) on shares of Bicycle Therapeutics in a research report on Friday, October 31st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Monday, December 22nd. Seven research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $19.73.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.